BJTJ-1837, a novel FXI activation-blocking antibody.

ABSTRACT:

Background

Factor (F)XI contributes to thrombosis development while it plays a limited role in normal hemostasis. FXI targeting has the potential for preventing and treating thrombosis with little bleeding risk.

Objectives

The aim of this study was to develop novel antibody therapeutics against FXI for the treatment of thrombosis-related diseases.

Methods

Mouse hybridoma technology was applied to screen for anti-FXI antibodies. Surface plasma resonance, enzyme inhibition, activated partial thromboplastin time, and prothrombin time assays were conducted to characterize the binding affinity and activity of antibodies. A cynomolgus monkey arterial venous shunt model was applied to validate the antithrombotic activities.

Results

A humanized antibody, BJTJ-1837, rep

SUBMITTER: He X 

PROVIDER: S-EPMC10017418 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature